Want to see ADUS full AI Analyst Report?
Top Page
Addus Homecare
(NASDAQ:ADUS)
Select Model
Select Model
Rating:80Outperform
Price Target:
$137.00
▲(16.09% Upside)
Action:Reiterated
Date:09/07/26
The score is driven primarily by strong financial performance (revenue growth, improving profitability over time, robust free cash flow, and materially lower leverage). Technicals add support with an established uptrend and positive MACD, while valuation is only moderately attractive at a ~20.9 P/E and no dividend yield provided.
Positive Factors
Revenue and earnings growth
Sustained revenue expansion alongside a higher net margin indicates that Addus is converting scale into stronger profitability. This combination supports reinvestment, improves the earnings base, and suggests the business can compound results if growth and cost control continue over the next several quarters.
Negative Factors
Senior leadership transition
The departure of a senior operating leader creates execution and succession risk during a period of expansion. Although the interim appointment provides continuity, Addus must maintain service delivery, integration discipline, and growth execution while establishing a durable long-term operating leadership structure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and earnings growth
Sustained revenue expansion alongside a higher net margin indicates that Addus is converting scale into stronger profitability. This combination supports reinvestment, improves the earnings base, and suggests the business can compound results if growth and cost control continue over the next several quarters.
Read all positive factors
Addus Homecare (ADUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.22B
Dividend YieldN/A
Average Volume (3M)208.28K
Price to Earnings (P/E)21.0
Beta (1Y)0.32
Revenue Growth15.88%
EPS Growth25.01%
CountryUS
Employees50,659
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)5.68
Shares Outstanding18,674,300
10 Day Avg. Volume189,761
30 Day Avg. Volume208,280
Financial Highlights & Ratios
PEG Ratio1.04
Price to Book (P/B)1.83
Price to Sales (P/S)1.39
P/FCF Ratio19.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$127.43Price Target Upside7.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)7.04
Revenue Forecast (FY)$1.52B
Addus Homecare Business Overview & Revenue Model
Company Description
Addus HomeCare Corporation, through its various subsidiaries, offers essential personal support services across the United States. The company primarily assists seniors, individuals with chronic illnesses or disabilities, and those at risk of hosp...
How the Company Makes Money
Addus HomeCare makes money by delivering home-based care services and receiving reimbursement from third-party payers based on authorized visits/hours of care or episodes of care, depending on the service line.
Key revenue streams:
1) Personal Ca...
Addus Homecare Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 02, 2026
Earnings Call Sentiment Positive
The call presented a broadly positive operational and financial picture: solid top-line growth (+7.7% revenue), meaningful EPS and adjusted EBITDA improvements, strong operating cash flow ($52.4M) and a strengthened balance sheet with reduced bank debt and sizable revolver availability. Personal Care and Hospice were key growth drivers (Personal Care same-store +6.5%; Hospice ADC +8.2%). Management also highlighted progress on productivity (caregiver app), hiring, and targeted M&A (entry into Indiana). Challenges noted include a weather-driven $1.5M revenue hit, elevated DSOs (timing-driven), a YoY decline in home health revenue, and a reversion in hospice revenue-per-day dynamics. Overall, positives (multiple strong metrics, cash flow and M&A runway, operating improvements) outweigh the contained challenges and one-time items.Positive Updates
Revenue Growth
Total revenue of $363.6M for Q1 2026, up 7.7% vs. $337.7M in Q1 2025.
Negative Updates
Weather-Related Revenue Impact
Widespread late-January weather event caused missed personal care visits and approximately $1.5M of lost revenue in Q1 2026; some missed visits could not be made up.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue of $363.6M for Q1 2026, up 7.7% vs. $337.7M in Q1 2025.
Read all positive updates
Company Guidance
Management guided that full‑year 2026 adjusted EBITDA margin should remain above 12% and the company expects an effective tax rate in the mid‑20% range (Q1 rate was 22.7%); gross margin was 31.9% in Q1 and is expected to remain relatively stable while adjusted G&A ran 19.6% of revenue (G&A 21.4%). Q1 results that frame the outlook included revenue of $363.6M (+7.7% YoY), adjusted EBITDA $44.5M (+9.7%), adjusted EPS $1.62 (+14.1%), operating cash flow $52.4M, cash on hand $103.1M, revolver capacity $650M (availability $547.8M), and total bank debt $94.3M (down $30M QoQ, with $10M revolver paydown in Q2 to date). Segment metrics noted: Personal Care $281.1M (77.3% of rev, +8.8% overall, same‑store +6.5%, same‑store hours +2.2% with a 2.0–2.5% hours target), Hospice $65.8M (18.1%, same‑store +7.7%, ADC 3,804, median LOS 23 days), Home Health $16.7M (4.6%).Addus Homecare Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.48B | 1.42B | 1.15B | 1.06B | 951.12M | 864.50M |
| Gross Profit | 477.75M | 461.87M | 375.02M | 339.88M | 299.74M | 269.85M |
| EBITDA | 167.37M | 153.44M | 120.61M | 106.56M | 83.14M | 80.70M |
| Net Income | 105.31M | 95.91M | 73.60M | 62.52M | 46.02M | 45.13M |
Balance Sheet | ||||||
| Total Assets | 1.46B | 1.44B | 1.41B | 1.02B | 937.99M | 947.59M |
| Cash, Cash Equivalents and Short-Term Investments | 99.57M | 81.62M | 98.91M | 64.79M | 79.96M | 168.90M |
| Total Debt | 108.82M | 208.62M | 273.13M | 175.18M | 178.05M | 263.55M |
| Total Liabilities | 308.33M | 352.00M | 442.14M | 317.73M | 304.45M | 373.24M |
| Stockholders Equity | 1.15B | 1.09B | 970.49M | 706.69M | 633.54M | 574.34M |
Cash Flow | ||||||
| Free Cash Flow | 153.06M | 103.79M | 110.38M | 102.79M | 96.81M | 34.84M |
| Operating Cash Flow | 162.41M | 111.51M | 116.43M | 112.25M | 105.11M | 39.49M |
| Investing Cash Flow | -48.01M | -32.50M | -354.61M | -119.24M | -106.59M | -42.02M |
| Financing Cash Flow | -106.00M | -96.30M | 272.30M | -8.18M | -87.45M | 26.34M |
Addus Homecare Technical Analysis
Positive
118.01
Price Trends
114.29
Positive
104.39
Positive
105.67
Positive
Market Momentum
1.09
Positive
57.53
Neutral
55.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADUS, the sentiment is Positive. The current price of 118.01 is below the 20-day moving average (MA) of 118.17, above the 50-day MA of 114.29, and above the 200-day MA of 105.67, indicating a bullish trend. The MACD of 1.09 indicates Positive momentum. The RSI at 57.53 is Neutral, neither overbought nor oversold. The STOCH value of 55.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADUS.
Addus Homecare Risk Analysis
Addus Homecare disclosed 32 risk factors in its most recent earnings report. Addus Homecare reported the most risks in the "Ability to Sell" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Addus Homecare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | $3.42B | 24.47 | 12.94% | 1.17% | 7.19% | 32.91% | |
80 Outperform | $2.22B | 21.01 | 9.57% | ― | 15.88% | 25.01% | |
77 Outperform | $2.96B | 10.29 | 150.20% | ― | 19.52% | 1337.90% | |
65 Neutral | $1.18B | 463.00 | -1.27% | 2.32% | 11.32% | -92.59% | |
62 Neutral | $1.33B | 41.82 | 9.51% | ― | 37.90% | 15.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ADUS
Addus Homecare
119.32
6.27
5.55%
NHC
National Healthcare
220.97
108.86
97.10%
USPH
US Physical Therapy
78.71
-3.53
-4.29%
PNTG
Pennant Group
39.31
14.48
58.32%
AVAH
Aveanna Healthcare Holdings
13.66
5.40
65.38%
Addus Homecare Corporate Events
Business Operations and StrategyExecutive/Board Changes
Addus HomeCare Announces Leadership Transition and Interim COO
Neutral
Aug 13, 2026
Addus HomeCare announced that President and Chief Operating Officer Heather Dixon left the company on August 7, 2026, marking a significant change in its senior leadership. The board and management publicly thanked Dixon for her service, noting he...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Addus HomeCare Reports Strong Q2 2026 Financial Growth
Positive
Aug 3, 2026
Addus HomeCare reported on August 3, 2026, that second-quarter 2026 net service revenues rose 8.0% year over year to $377.4 million, with net income up 25.2% to $27.6 million, or $1.49 per diluted share, and adjusted EBITDA increasing 11.9% to $49...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.